HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Robert S McKelvie Selected Research

irbesartan

9/2015Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
8/2015Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
7/2015Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
6/2015Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
6/2015The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
1/2015International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
11/2014History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction.
11/2014A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.
9/2014Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
7/2014Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Robert S McKelvie Research Topics

Disease

57Heart Failure
09/2015 - 02/2002
5Myocardial Infarction
11/2014 - 07/2004
4Coronary Artery Disease (Coronary Atherosclerosis)
11/2015 - 11/2007
4Atrial Fibrillation
07/2014 - 08/2004
4Hypertension (High Blood Pressure)
07/2011 - 08/2004
2Sudden Death
09/2011 - 10/2005
2Diabetes Mellitus
07/2011 - 08/2004
2Left Ventricular Dysfunction
02/2008 - 09/2006
2Ventricular Remodeling
09/2006 - 09/2005
1Peripheral Vascular Diseases (Peripheral Vascular Disease)
07/2013
1Body Weight (Weight, Body)
02/2012
1Weight Gain
02/2012
1Fibrosis (Cirrhosis)
09/2011
1Systolic Heart Failure
09/2011
1Sleep Apnea Syndromes (Sleep Apnea)
05/2011
1Renal Insufficiency (Renal Failure)
05/2011
1Muscle Weakness
01/2006
1Muscular Atrophy (Muscle Atrophy)
01/2006
1Unstable Angina
10/2005
1Cardiac Arrhythmias (Arrythmia)
03/2005
1Hypotension (Low Blood Pressure)
10/2004
1Hyperkalemia
10/2004
1Chronic Obstructive Pulmonary Disease (COPD)
08/2004
1Myocardial Ischemia (Ischemic Heart Diseases)
08/2004

Drug/Important Bio-Agent (IBA)

15irbesartanFDA LinkGeneric
09/2015 - 02/2010
15candesartanIBA
09/2015 - 10/2003
12Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
07/2011 - 01/2003
9Brain Natriuretic Peptide (Natrecor)FDA Link
08/2015 - 09/2005
7pro-brain natriuretic peptide (1-76)IBA
08/2015 - 03/2008
6Angiotensin Receptor AntagonistsIBA
07/2011 - 02/2002
5AngiotensinsIBA
09/2014 - 10/2004
5Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
07/2011 - 10/2004
4EnalaprilFDA LinkGeneric
04/2009 - 10/2003
4Biological Markers (Surrogate Marker)IBA
03/2008 - 09/2005
3Natriuretic PeptidesIBA
03/2015 - 03/2008
3AldosteroneIBA
02/2008 - 10/2004
3Angiotensin IIIBA
02/2008 - 01/2003
3Digoxin (Digitek)FDA LinkGeneric
02/2007 - 08/2004
3Growth Hormone (Somatotropin)IBA
06/2006 - 03/2003
2Atrial Natriuretic Factor (ANF)IBA
02/2008 - 09/2005
2Norepinephrine (Noradrenaline)FDA LinkGeneric
02/2008 - 09/2005
2Matrix MetalloproteinasesIBA
02/2008 - 09/2006
2Epinephrine (Adrenaline)FDA LinkGeneric
02/2008 - 09/2005
2Metoprolol (Lopressor)FDA LinkGeneric
09/2006 - 10/2003
2Captopril (Capoten)FDA LinkGeneric
01/2005 - 07/2004
2valsartan (Vals)FDA Link
01/2005 - 07/2004
1rosuvastatin (Crestor)FDA Link
01/2015
1bipiperidyl mustard (BPM)IBA
07/2014
1tilisololIBA
07/2014
1Methylenebis(chloroaniline) (MOCA)IBA
06/2014
1GoldIBA
07/2013
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
07/2013
1Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA
01/2013
1Collagen Type I (Type I Collagen)IBA
09/2011
1OsteopontinIBA
09/2011
1Collagen Type III (Type III Collagen)IBA
09/2011
1CollagenIBA
09/2011
1Angiotensin II Type 1 Receptor BlockersIBA
07/2011
1DiureticsIBA
02/2010
1Spironolactone (Aldactone)FDA LinkGeneric
02/2010
1OxygenIBA
09/2008
1Tissue Inhibitor of Metalloproteinase-1IBA
02/2008
1Endothelin-1 (Endothelin 1)IBA
02/2008
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
09/2006
1ReninIBA
09/2005
1Neurotransmitter Agents (Neurotransmitter)IBA
09/2005
1Aldosterone AntagonistsIBA
08/2005
1Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
03/2005
1candesartan cilexetil (Amias)FDA Link
01/2005
1CholesterolIBA
11/2004
1HDL CholesterolIBA
11/2004
1Blood Glucose (Blood Sugar)IBA
11/2004
1CreatinineIBA
10/2004
1NitratesIBA
08/2004

Therapy/Procedure

8Long-Term Care
09/2014 - 08/2004
3Resistance Training
11/2015 - 01/2006
2Activities of Daily Living (ADL)
02/2012 - 01/2006
1Drug Therapy (Chemotherapy)
07/2011
1Palliative Care (Palliative Medicine)
05/2011
1Transplants (Transplant)
11/2007
1Complementary Therapies (Alternative Medicine)
03/2006
1Combination Drug Therapy (Combination Chemotherapy)
01/2006
1Polypharmacy
03/2005
1Length of Stay
01/2004